NCT05141201Active, not recruiting
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)
Saphnelo for Intravenous Infusion 300 mg Specific Use Result Study All Patient Investigation in Patients With Systemic Lupus Erythematosus
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
To collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus in the real-world post-marketing setting.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1620 (actual)
- First submitted
- 19 Nov 2021
- Start date
- 21 Dec 2021
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Lupus (SLE)
- NCT number
- NCT05141201
What you commit to
- Study type: Observational
- Participants enrolled: 1620
- From 21 Dec 2021 to the primary completion date, 31 Mar 2027
- 47 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
- \-
Who the study is looking for
- patients with systemic lupus erythematosus insufficiently responding to currently available treatment -
Sex: All · Does not accept healthy volunteers
Sites (47)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.